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An empirical method of sample size determination for building prediction models was proposed recently.
Permutation method which is used in this procedure is a commonly used method to address the problem
of overﬁtting during cross-validation while evaluating the performance of prediction models constructed
frommicroarray data. But major drawback of such methods which include bootstrapping and full permu-
tations is prohibitively high cost of computation required for calculating the sample size.
In this paper, we propose that a single representative null distribution can be used instead of a full per-
mutation by using both simulated and real data sets. During simulation, we have used a dataset with zero
effect size and conﬁrmed that the empirical type I error approaches to 0.05. Hence this method can be
conﬁdently applied to reduce overﬁtting problem during cross-validation. We have observed that pilot
data set generated by random sampling from real data could be successfully used for sample size deter-
mination. We present our results using an experiment that was repeated for 300 times while producing
results comparable to that of full permutation method. Since we eliminate full permutation, sample size
estimation time is not a function of pilot data size. In our experiment we have observed that this process
takes around 30 min.
With the increasing number of clinical studies, developing efﬁcient sample size determination methods
for building prediction models is critical. But empirical methods using bootstrap and permutation usually
involve high computing costs. In this study, we propose a method that can reduce required computing
time drastically by using representative null distribution of permutations. We use data from pilot exper-
iments to apply this method for designing clinical studies efﬁciently for high throughput data.
 2014 Elsevier Inc. All rights reserved.1. Introduction is costly and difﬁcult but it constitutes a key task in performingOne of the main reasons to utilize high dimensional data from
microarrays in clinical research is to develop statistical models that
predict clinical outcomes such as, time to recurrence, progression
of disease and survival of patients. Finding high quality samplesclinical studies. The task of ﬁnding minimum number of samples
for scientiﬁc study is very important to minimize the wastage of
valuable resources and retain clinical utility of the experiment.
Determination of sample size based on sound technical basis is a
signiﬁcant part of guidelines set by Institutional Review Board
(IRB).
Several important methodologies were proposed to determine
sample size for microarray experiments. Liu and Hwang report a
formula suitable for comparison studies with multiple
independent samples [1]. Methods which introduce the concept
of controlling False Discovery Rate (FDR) in microarray analysis
were further developed to estimate power and sample size [2–5].
These methods are aimed at discovering statistically valid
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genetic make-up of diseases such as cancer, diabetes and other
immune diseases these methods suffer from less-than-desirable
accuracy for medical practice. This implies that one has to consider
the necessity of multiple parameters in the prediction models, as
well as the variations from experimental platform. Recent FDA
clearance of Affymetrix™ system as a diagnostic platform presents
an example of rapid upgrade in reliability of such platforms for use
in clinical settings [6]. Statistical prediction models such as one
used in OncotypeDX™ which employs multiple biomarkers vali-
date the value of such predictive models. These models have
formed a trend in many clinical trials in combination with co-diag-
nosis approach [7,8].
Recently, Pang and Jung provided an idea to rigorously deter-
mine the sample size required to construct such a predictive model
[9]. It estimates empirical power of a suggested sample size using
simulated data from bootstrapping based on a predictive model
developed using pilot project data. A proof was given by Jung
and Young [10] that demonstrates the structure of covariance from
pilot data and bootstrapped data from the pilot data are approxi-
mately identical. They also suggest a method to estimate empirical
power when the response variable is of survival type. Since this
method constructs individual prediction models from numerous
simulated data sets and performs cross-validation and permuta-
tion each time, it reduces the problem of over-ﬁtting while adding
expensive computation time for repeated calculations.
The concept of prediction–validation method is the ﬁrst of its
kind to determine the sample size of multi-dimensional data [9].
However, it remains a concern that it requires lot of time to deter-
mine proper sample size of a data set with many variables. This
approach would be more practical if the computation complexity
could be reduced. We were inspired by an observation that a set
of simulated data sets from pilot data seem to generate similar
non-centrality parameters when each set was estimated by maxi-
mum likelihood method. Thus, it seemed reasonable to assume
that a carefully selected single null distribution could be re-used
in other sets for adjusting p-values. Our current study provides a
method to determine sample size for the case of binary response
variables using this idea. We demonstrate empirical evidence by
extensive simulation which supports the fact that sample size
can be conveniently approximated.
2. Methods
It is known that statistical power can be estimated from a num-
ber of simulated data by bootstrapping based on a predictionmodel
from pilot data. A prediction model is constructed for each simu-
lated data. Validation of the models can estimate the empirical
power from the ratio of valid models over the total set of simulated
data [9]. We carry out a v2-test for each model from a simulated
data and regard the model to be valid when the p-value is less than
the signiﬁcance level of 0.05. This procedure heavily depends on
repeated CV with permutation on simulated data. Consequently,
it results in immense computational cycles which prohibit practical
applications of this method.
We have created a representative permutation null distribution
from one randomly chosen simulated data among those of showing
the highest marginal frequency within the group of whole simu-
lated data. Details of each step to determine this null distribution
is explained in the following section.
2.1. Bootstrapping data generation
In order to estimate empirical power, many simulated data sets
are required. A small-sized pilot data is deﬁned as
M ¼ fwi; ðxi1; . . . ; xigÞ; i ¼ 1; . . . ;mg, where wi is a response variablefor ith subject and xig is gth gene expression level for ith subject.
That is, there are m individuals and the number of features is g.
The sample mean and the standard deviation are denoted by xj; sj
respectively for feature (or genes in our example) jð¼ 1; . . . ; gÞ.
Let fM ¼ fyi; ðzi1; . . . ; zigÞ; i ¼ 1; . . . ;Ng be a bootstrapped simulated
data, where yi is a response variable in the bootstrap sample,
zij ¼ ðxi0 j  xjÞei=sj for random variables of e1; . . . ; eN  i:i:d:Nð0;1Þ,
and i0 is a randomly chosen number from ð1; . . . ;mÞ. Note that
bootstrapped sample size N can differ from pilot sample size m
(N > m). We repeat this process to generate many simulated data
sets to use when estimating empirical power. It is known that
CovðfMjMÞ ! CovðMÞ; as n!1 [10].
In order to construct a multiple regression prediction model,
candidate markers are selected among thousands of genes. It is
done by univariate logistic regression applied to the pilot data,
and it selects t candidate markers. The ID of selected genes are rep-
resented as ð~1; . . . ;~tÞ, and their expression values, Zi ¼ ðZi~1; . . . ; Zi~tÞ
for the individual i respectively.
Risk score of an individual ið¼ 1; . . . ;NÞ can be represented as
p^i ¼ Pðyi ¼ 1 j zÞ ¼ 1=ð1þ expfbTZigÞ, the probability estimated
from multiple logistic regressions. Therefore, Bernoulli trial of
probability p^i allows evaluation of binary response variable,
yiði ¼ 1; . . . ;NÞ which corresponds to the simulated data generated
from bootstrapping. By repeating the procedure one can generate a
data set of bootstrap microarray data, fMb ¼ fyi; ðzi1; . . . ; zigÞg,
where i ¼ ð1; . . . ;NÞ; b ¼ ð1; . . . ;BÞ, each of which are of sample
size N.
2.2. Methods of prediction and evaluation
Since the statistical power is the conditional probability of
rejecting the null hypothesis when it is really false, we can esti-
mate by calculating the proportion of rejection, that is, the p-values
less than the level of signiﬁcance. Thus we need to clarify what p-
value is in this situation. Here we deﬁned p-value for the speciﬁc
model based on the comparison between predictive values and ori-
ginal values.
Prediction: We used multiple logistic regression and 3-fold CV
with permutation method to predict y^i, the predicted response
variables of yi in fMb. The construction of prediction models for
each simulated data sets, fMb starts with selecting top t predictors
through univariate logistic regression in each data set as explained
in detail below. We tried to reduce the concern of overﬁtting of
cross-validation procedure by using permutation method. Thus
the vector of predicted values y^ ¼ ðy^1; . . . ; y^NÞ is determined:
– Divide the dataset into K (nearly) equal-sized subsets and for
ﬁxed kðk ¼ 1; . . . ;KÞ, remove kth subset.
– Perform a univariate logistic regression analysis on each of the
genes using the remaining ðK  1Þ subsets and ﬁnd top t
predictors.
– Build a multiple logistic regression model with top t predictors
and ﬁnd the predicted values using the remaining kth subset.
Those predicted values y^i, where i is the index of kth subset
composes the predicted vector y^.
Evaluation: The similarity of y^i and yi can be calculated by
homogeneity test based on v2-statistic in bth bootstrapped data.
The null hypothesis is, H0 : Pðy^ijyi ¼ 0Þ ¼ Pðy^ijyi ¼ 1Þ, and
alternative hypothesis is H1 : Pðy^ijyi ¼ 0Þ – Pðy^ijyi ¼ 1Þ. Thus the
performance of prediction model can be evaluated by the p-value
of homogeneity test for 2  2 contingency table:
– Calculate the homogeneity chi-squared statistic (v2b) of bth
bootstrapping data, fMb using two vectors y^ ¼ ðy^1; . . . ; y^NÞ and
y ¼ ðy1; . . . ; yNÞ.
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response variable data, fyi : i ¼ 1; . . . ;Ng and covariates
fðzi1; . . . ; zigÞ : i ¼ 1; . . . ;Ng for each fMb (p ¼ 1 . . . ; P), where P
is total number of permutations.
– Calculate v2-statistic (v2p) by applying multiple logistic regres-
sion and CV for pth permutation data at the same condition.
After repeating this procedure P times, then v2p (p ¼ 1 . . . ; P)
compose the permutation null distribution of simulated data,fMb.
– Calculate unbiased p-value, pb for fMb by calculating the
following:pb ¼ P1
XP
p¼1
Iðv2b 6 v2pÞ where b ¼ ð1; . . . ; BÞ ð1Þ2.3. Power estimation for given sample size
The estimation method allows one to calculate power as
follows.
(A) Specify the design parameters
– ða;1 bÞ: type I error rate and power
– g: number of total genes
– t: number of candidate genes for prognostics, number of
genes to be used as independent variables in the multiple
logistic regression model
– ð~1; . . . ;~tÞ: the ID of candidate genes for prognostics, the ID
of genes to be used as independent variables for multiple
logistic regression model
– ~bj: The size of effect of a candidate gene for prognostics, ~j.
A regression coefﬁcient of the independent variable, zj in
the multiple logistic regression model
– m: number of samples in a small scale pilot data
(B) In order to generate a pilot data of sample size m, we per-
form microarray experiments and then generate as many
as B sets of simulated microarray data,fMb ¼ fyi; ðzi1; . . . ; zigÞg, where i ¼ ð1; . . . ;NÞ; b ¼ ð1; . . . ;BÞ of
sample size N, by bootstrapping according to the procedure
explained in the previous section.
(C) Calculate statistical power
(i) Perform a univariate logistic regression analysis on
each of the genes and construct multiple logistic regres-
sion models using simulated data sets,fMb generated by
bootstrap in the same way as was carried out with pilot
data.
(ii) Perform k-fold cross-validation pre-determined from
parameter design process in (A), and calculate v2-sta-
tistic based on homogeneity test.
(iii) Calculate marginal sums of response variables for all
the simulated data sets, and randomly select a data
set, fMb within the group that has the most frequent
marginal sum.
(iv) Repeat the following procedure for the selected data,fMb as many as P times to generate the representative
permutation null distribution, fv2b0p : p ¼ 1; . . . ; Pg.– shufﬂe the binary response variable
– construct a prediction model
– perform k-fold CV
– perform homogeneity test and calculate v2 test statis-
tic, v2b0p.(v) Calculate p-value, pb, for each of B simulated data set
using the representative permutation null distribution.pb ¼ P1
XP
p¼1
Iðv2b 6 v2b0pÞ where b ¼ 1; . . . ;B(vi) The empirical power, ð1 b^NÞ is estimated as the ratio
of data among the B simulated data sets which are
determined as valid with signiﬁcance level of a.ð1 b^NÞ ¼ 1B
XB
b¼1
Iðpb < aÞ2.4. Method of sample size determination
It is possible to determine the minimum sample size whose
power exceeds the pre-determined power, ð1 bÞ when using
the suggested method of power estimation. This procedure can
be further optimized by utilizing binary search algorithm in order
to search the minimum sample size. Considering that power esti-
mation is the most time consuming task, starting to search for
the smallest N after which power estimate is larger than 80% by
better selection of range of N can contribute to reduction of calcu-
lation time. Since it is known that a sample size determination
without permutation underestimates the sample size, one can start
searching at a larger number than the underestimated sample size,
and can expect reduction of time for searching.
3. Results
3.1. Simulation studies
Our methodology and amount of time required for statistical
power calculation was tested using simulations. Simulated data
of size N was generated as fðzi1; . . . ; zi1000Þ; i ¼ 1; . . . ;Ng based on
multivariate normal distribution, MVNð0;RÞ with 1000(¼ g) genes,
whose gene expression data has mean of 0. The structure of covari-
ance matrix (R) is a block-diagonal matrix of size 1000 1000.
There exist 50 blocks in the matrix and each block has an autocor-
relation structure of size d d. In order to introduce variation of
block size, we generated random variables from [(1000/50) ⁄ 0.7,
(1000/50) ⁄ 1.3] to be used for d. Correlation coefﬁcient to be used
in each block was randomly generated using uniform distribution
between 1 and 1. That is,R ¼
Rq1 0          ..
.
0 Rq2 0
. .
. . .
. ..
.
..
.
0 Rq3 0
. .
. ..
.
..
. . .
.
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10001000where,Rqj ¼
1 qj    qd2j qd1j
qj 1
. .
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. ..
.
..
. . .
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;
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50) ⁄ 0.7, (1000/50) ⁄ 1.3] and qj are random variables from
U(1,1).
We followed a similar approach for constructing covariance
matrices but reduced the size of the covariance matrix for the ease
of calculation [11,12]. According to Guo et al. [11], this correlation
structure provides a reasonable basis since some group of genes
are connected each other in their pathways and there are weaker
relationships between gene groups. That is the reason why the
correlations between groups are zero. And the basic assumption
within group is that the gene order has some meaning so that
the correlations decline exponentially with respect to the
difference between indices. Here we impose more variability by
generating common correlation coefﬁcient qj from uniform distri-
bution since the correlation coefﬁcient is between 1 and 1 and by
varying the block size. Also we ease and include another correla-
tion structure which is described in Section 4 and Appendix B.
The top t (t ¼ 3 in this study) genes were regarded as signiﬁcant
and were used in multiple logistic regression model with equal size
of effect (b). The effects from the rest of genes were assigned as 0.
Response variable data of individual i was generated using the fol-
lowing method.
yi  BernoulliðpiÞ
where,pi ¼
1
1þ expfðb0 þ b1z1 þ    þ btztÞg
Repeating this procedure, 1000 simulated data setsMsimul:b ¼ fyi; ðzi1; . . . ; zi1000Þ; i ¼ 1; . . . ;Ng; b ¼ 1; . . . ;1000
were generated and used for subsequent calculations.
To check the type I error in this simulation, 1000 simulated data
sets of N ¼ 50 with effect size b0 ¼ . . . ¼ b1000 ¼ 0 of 1000 genes
were generated. Each simulated data set used top 3 of the most sig-
niﬁcant genes from univariate analyses of 1000 genes to construct
a multiple logistic regression model. This model was used to per-
form 3-fold CV and estimated N ¼ 50 predicted outcome values
followed by the procedure described in Section 2.3. The power is
the ratio of valid predictions determined by chi-square statistic
over 1000 data sets. We reduced the overﬁtting of our model by
CV with permutation [9], and conﬁrmed that type I error was
0.047. This is closer to the preset signiﬁcance level of 0.05 than
0.106 which is estimated without permutation, that is, naive use
of chi-squared distribution with 1 degree of freedom as a null dis-
tribution of 2  2 contingency table.
One unavoidable drawback of this procedure is high computing
cost for permutations. Our main idea to reduce the cost of permu-
tation is to perform permutation only once with a representative
bootstrap data, and reuse null distribution for other data sets. It
is based on this insight that the whole simulated data sets were
generated from a single pilot data and thus they can be repre-
sented by a single null distribution. This is visible in a plot of
cumulative distribution functions (CDFs) of non-central v2-distri-
butions from permutation null distributions using 1000 simulated
data sets. (Appendix A).
A probable representative simulated data set can be selected
with one that has the most common null distribution among
1000 data sets. This is the case with microarray data, where only
response variables are shufﬂed. It means that, if the frequencies
of 0’s and 1’s in the response variable of two bootstrap data are
the same, they will share a null distribution. Histograms in Fig. 1
are frequencies of marginal sums with yi ¼ 0. The histogram in
Fig. 1(a) shows the most frequent marginal sum with yi ¼ 0 is
located around 25. (Appendix D) This subset of simulated data isconsisted of 121 data sets. Since our basic strategy to select repre-
sentative null distribution is random selection from them, we try
to check whether this random selection affects the level of signiﬁ-
cance or not. We obtained all 121 power values assuming that each
and every bootstrapped data is used to calculated permutation null
distribution. The 121 estimated power values have mean of 0.044
and standard deviation of 0.012. A more accurate empirical power
based on CV with full permutation gives 0.047 while the signiﬁ-
cance level is 0.05.
The empirical power is shown as a horizontal reference line at
0.047 in Fig. 1(a). Depending on the marginal sum of the selected
data set, the mean power approximation (solid line) is near the ref-
erence power at marginal sum of 25, and the standard deviation
(dashed line) is less than or close to 0.01.
Fig. 1(b) shows results from data set with 1000 genes, three of
which have the effect size of 5 (b1 ¼ b2 ¼ b3 ¼ 5), and rest have 0.
The power was 0.909 when calculated by full permutation method.
The estimation of power based on our proposed method using
representative null distribution is 0.903 ± 0.010 (mean ± sd). The
variation is small enough to allow reliable power estimation and
sample size determination. This implies that it is possible to
perform robust power estimation irrespective of the selection of
simulated data sets. We also generated simulated data sets by
using other methods included in Cai et al. and Pang et al. [9,13],
and these data sets also lead to the same conclusion (Appendices
B and D).
A closer look at our newly suggested method to observe the
robustness against the perturbation of parameters is carried out
as follows. Before a series of simulations were performed, we
generated 100 pilot data sets each for 27 combinations of three
parameters by varying size of the pilot data with (m) as 30, 50,
70; autocorrelation coefﬁcient in covariance structure (q) as 0.3,
0.5, 0.7; effect size (b) as 0.5, 1, 1.5; and block size (d) as 10. The
number of genes was reduced to 100 since the complexity of the
system is plausible. Sample size determination for 100 pilot data
sets of speciﬁc m, q, b were calculated with (1 b) = 0.8. Each his-
togram in Fig. 2 shows the distribution of sample size for the case
of b ¼ 0:5, with various m, q using 100 pilot data sets. Other com-
binations of parameters are shown in Appendix C (b ¼ 1 and
b ¼ 1:5). Fig. 2 shows a trend of decreasing or stabilizing variance
of sample size determines as the pilot data size m increases. This
was reported by Jung and Young [10]. The trend of smaller deter-
mines of sample sizes when the autocorrelation coefﬁcient (q)
among genes gets larger is also visible. This trend is present when
beta is increased, and is shown in Fig. 2 and Appendix C. They also
show another trend that larger beta results in smaller determines
of sample size as expected.
3.2. Real data example
We used the data from Christensen et al. and Gravier et al. to
apply our sample size determination method [14,15]. Gravier
et al. data was obtained from patients with early stage small, inva-
sive ductal carcinomas (T1T2N0) with no auxiliary lymph node
involvement to investigate the metastasis of small node-negative
breast carcinoma. High dimensional experimental data was pro-
duced from 168 patients using array-CGH. This data set contains
genome information with 2905 features for each individual. 111
patients have no metastasis and the rests (57) are of poor progno-
sis with early metastasis (data source: https://github.com/ramhis-
er/datamicroarray/blob/master/data/gravier.RData).
Christensen et al. compared CpG methylation patterns in 217
pairs of cancer and normal tissues. They used Illumina GoldenGate
methylation bead array for data production which included 1413
sites within 773 genes (data source: https://github.com/ramhis-
er/datamicroarray/blob/master/data/christensen.RData).
Fig. 1. Distribution and power analysis for 1000 simulated data sets with N ¼ 50. Each column contains data sets with the same number of samples whose response variable,
yi ¼ 0. Type I error values for each column were plotted as solid (mean) and dashed (standard deviation) lines. (a) 1000 simulated data sets were randomly generated with
b ¼ 0. (b) 1000 simulated data sets were randomly generated with b ¼ 5. (c and d) 1000 simulated data sets were generated from an experimental data (Gravier et al.’s [15]
and Christensen et al.’s [14], respectively).
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Gravier et al. to construct one of our pilot data sets. Same proce-
dure of obtaining the representative null distribution and power
was applied, and the results match to that of our simulations.
We repeated the same procedure with the data used by
Christensen et al. and their histograms and power values from full
permutation method are shown in Fig. 1(c) and (d).
In order to estimate the most desirable size of a pilot data and
the number of repeats for sample size calculation, we randomly
selected pilot data sets of size m (m ¼ 30;50;70) from a pool of
Gravier et al.’s 168 patients’ microarray data, and determined the
sample size for each pilot data. For each m, 300 pilot data were
generated for repeated sample size calculation. A single sample
size determination from pilot data involved multiple power
calculations using 1000 bootstrap data and representative null
distribution of permutations.
Fig. 3 shows the distribution of 300 determined sample sizes
which appear to have larger variance than expected fromsimulation. As the pilot data size increases, mean of the deter-
mined sample sizes also tend to increase. Since small pilot data
sizes impose a disadvantage of poor representation of the popula-
tion, it results in increase of variance in sample sizes. It is possible
to achieve the targeted power threshold by observing the change of
sample size variance and adjusting the size of bootstrap data
iteratively.
Determination of sample size requires pilot data and this is true
for both full permutation method and our method. It is hard to
predict a reasonable size of a pilot data set. We decided to follow
the examples of previous studies, in which the pilot data size were
about 50. It is possible to consider using public data, if it exists, as a
pilot data set, which shares the platform and disease type, etc.
As computational cost is a critical factor to highlight the
practicality of this method, we present our computational
resources and results in this section. We have used 8 cores (Intel
Xeon CPU E5-2690 2.90 GHz, dual 4 cores CPU) for parallel process-
ing. Our method to calculate sample size took about 30 min. This is
Fig. 2. Determination of sample size with varied number of pilot data size (m) and autocorrelation coefﬁcient (q). Each histogram represents a distribution of 100 estimations
of sample size with b ¼ 0:5 from randomly generated pilot data sets.
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required for full permutations method (Table 1). The calculation
was performed using a parallel processing machine. The amount
of total CPU time was obtained by adding up CPU times reported
by individual CPU’s within the parallel machine. This was due to
the restriction by the supercomputer center that prohibits jobs run-
ning for an unbearably long time when run in a single CPU mode.
4. Conclusion and discussion
In Section 3.1 we can verify that the type I error is controlled. To
conﬁrm whether type I error is affected by correlation structure or
not, we also generated simulated data sets followed by the corre-lation structure used other methods included in Cai et al. [13], Pang
et al. [9], and the most general case (no structure but positive def-
inite). We compared the powers from full permutation to proposed
method (Appendix B). The results are shows that type I error is
controlled and the similar results as in Fig. 1(a).
We provide Appendix E where we compared empirical powers
between naive use of chi-squared distribution with 1 degree of
freedom and use of the representative null distribution under var-
ious situations. The powers increase as the number of folds
increase without a control of type I error if we use naive chi-
squared distribution as the null distribution. The powers are
slightly less when using 2 or 10 folds CV than 3 or 5 folds. Besides,
the 3-fold CV gives the smaller standard deviation, therefore, we
Fig. 3. Distribution of determined sample sizes with various pilot data sets (m ¼ 30;50;70) randomly selected from Gravier et al. data.
Table 1
Computational cost comparison between full permutation and proposed method
(mean ± sd). Full permutation method represents computing time for one execution
according to the number of 30, 50 and 70, respectively. Proposed method also shows
an (mean ± standard deviation) of computing time of 300 repeats in Fig. 3.
m ¼ 30 m ¼ 50 m ¼ 70
Full permutation method 19.2 days 25.1 days 21.4 days
Proposed method 28.7 ± 13.5 min 28.9 ± 13.5 31.1 ± 12.5
D.-S. Son et al. / Journal of Biomedical Informatics 53 (2015) 355–362 361use 3-fold CV to evaluate. This is empirical evidence of overﬁtting
of CV method and makes use of permutation null distribution
necessary.
A new paradigm of introducing genome-wide data in search of
new markers has emerged and presents us with products that use
multiple clinical diagnostic markers. These products seem to
promise higher potential and further utility since they can reﬂect
the correlation between multiple genes involved in disease
mechanisms.
The proposed method of sample size determination can be
adopted by studies that try to develop multiple marker prediction
models, and it is especially appropriate for clinical studies with
many binary variables. It still remains a hurdle that the variance
of calculated sample size from real data (Gravier et al.’s) is larger
than that of simulated calculations. However, it is not difﬁcult to
resolve this issue since sample size calculations form a normal dis-
tribution and the variance can be reduced by taking the mean of
the sample size estimates. Fig. 3 depicts the distribution of sample
size estimates that resemble normal distribution. We have tried
repeating the sample size determination by 3, 5 and 10 times to
reduce the variance and obtain the estimator close to mean. This
procedure is a cost effective option compared to performing full
permutation method.
Our suggested method enables practical sample size determina-
tion by allowing calculation in less than 10 repetitions. A realistic
scenario of performing microarray experiments are usually made
up of several batches, thus sample size determination can be per-
formed as each batch is added without difﬁculty during the initial
stage of a clinical research.Authors’ contributions
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